Differing manifestations of respiratory syncytial virus-associated severe lower respiratory tract infections in human immunodeficiency virus type 1-infected and uninfected children

Pediatric Infectious Disease Journal

Volumn 20, Issue 2, 2001, Pages 164-170

  Madhi, Shabir A ^a   Venter, Marietjie ^b   Madhi, Anas ^a   Petersen, Karen ^a   Klugman, Keith P ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b National Institute of Virology   (South Africa)

Author keywords

Human immunodeficiency virus type 1; Pneumonia; Respiratory syncytial virus

Indexed keywords

MONOCLONAL ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY;

ARTICLE; BACTEREMIA; CHILD; CHILDHOOD MORTALITY; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNOFLUORESCENCE; INFANT; LEUKOCYTE COUNT; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTH AFRICA; VIRUS CHARACTERIZATION;

AGE FACTORS; ANTIBODIES, MONOCLONAL; BACTEREMIA; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FEVER; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; INFANT, NEWBORN; LEUKOCYTE COUNT; MALE; PNEUMONIA; PREVALENCE; PROSPECTIVE STUDIES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY TRACT INFECTIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; SEASONS; SOUTH AFRICA;

EID: 0035125513     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200102000-00010     Document Type: Article

References (28)

1. Respiratory syncytial viral infection in children with compromised immune function
2. The epidemiology of acute respiratory tract infection in young children: Comparison of findings from several developing countries
3. Epidemiology of acute lower respiratory diseases in children
4. Increased burden of respiratory virus associated severe lower respiratory tract infections in HIV-1 infected children
5. Respiratory syncytial virus infection in human immunodeficiency virus-infected children
6. Respiratory virus infections
7. Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IGIV
8. Care of human immunodeficiency virus-infected children in developing countries. International Working Group on Mother-to-Child transmission of HIV
9. Determinants of mother-to-child transmission of human immunodeficiency virus type 1 infection in a cohort from Durban, South Africa
10. Increased disease burden and antibiotic-resistance of bacteria causing severe community-acquired lower respiratory tract infections in HIV infected children
11. Pediatric investigators collaborative network in infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection
12. Rapid detection of respiratory viruses by shell vial culture and direct staining by using pooled and individual monoclonal antibodies
13. Analysis of respiratory syncytial virus genetic variability with amplified cDNAase
14. C-reactive protein in respiratory virus infections
15. Induced sputum in the diagnosis of Pneumocystis carinii pneumonia in HIV positive children using direct immunofluorescent antibody (DFA) technique
16. Bacterial coinfection in children hospitalized with respiratory syncytial virus infections
17. Risk of secondary bacterial infection in infants hospitalized with respiratory syncytial virus infection
18. The clinical spectrum of respiratory syncytial virus disease in The Gambia
19. Pneumonia in childhood
20. Erythrocyte sedimentation rate, white blood cell count and serum C-reactive protein in assessing etiologic diagnosis of acute lower respiratory infections in children
21. Bacterial pneumonia
22. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
23. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome
24. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis
25. Respiratory syncytial virus vaccines